NewsFlash »

Vaxil BioTherapeutics Initiates Phase 1/2 Clinical Trial Of ImMucin - Vaxil Biotherapeutics, a vaccine development company, has begun recruiting multiple myeloma patients for a Phase 1/2 clinical trial for its therapeutic vaccine ImMucin. Patients in the clinical trial will receive between six and twelve injections of ImMucin over three to six months. Researchers will follow up with patients for an additional six months. The clinical trial, which will evaluate the safety of ImMucin, will be held in Israel, where Vaxil is based. For more information, please see the Vaxil BioTherapeutics press release and the clinical trial description.

Senesco Plans Phase 1/2 Study Of SNS01-T – Senesco Technologies, a biotechnology company, announced plans to file by the end of 2010 for approval of a Phase 1a/2b study of SNS01-T in multiple myeloma patients. SNS01-T has shown promising results pre-clinical studies involving mice. If approved, the trial will begin in the first half of 2011. For more information, please see the Senesco press release.

International Society Of Hematology Congress – The International Society of Hematology will hold its 33rd annual congress in Jerusalem between October 10 and 13. Hematologists from around the world will gather to discuss the latest research, therapies, and tools available in the field. For more information, please see the Hematology Congress 2010 website.

Clinical Insights Educational Program – Dr. Robert Orlowski of the MD Anderson Cancer Center will be chairing an educational program in Houston on October 15. The program will feature seminars by some of the leading myeloma researchers, including Drs. Kenneth Anderson, Sagar Lonial, William Bensinger, Nikhil Munshi, and Irene Ghobrial. Seminar topics include front-line therapy, stem cell transplant, relapsed/refractory disease, supportive care, and clinical trials. The program will close with a question and answer panel by the faculty. For more information, please see the Multiple Myeloma Research Foundation website.

For a more detailed listing of myeloma-related events, please check the Myeloma Beacon Events Calendar.